Free tool
FAERS Monitor: Alvaiz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216774 or its brand name (Alvaiz, Eltrombopag Choline). Reports on generic versions are filed under their own applications.
Reports
3,893
Serious
3,620
93% of reports
Hospitalization
1,462
Death reported
632
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective550
- off label use494
- platelet count decreased426
- thrombocytopenia254
- product use in unapproved indication247
- therapy non-responder210
- death144
- immune thrombocytopenia143
- pneumonia139
- pyrexia137
- headache136
- treatment failure115
- anaemia108
- sepsis106
- pancytopenia103
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 3 |
| 2009 | 47 |
| 2010 | 81 |
| 2011 | 47 |
| 2012 | 43 |
| 2013 | 87 |
| 2014 | 146 |
| 2015 | 246 |
| 2016 | 130 |
| 2017 | 138 |
| 2018 | 203 |
| 2019 | 293 |
| 2020 | 245 |
| 2021 | 310 |
| 2022 | 293 |
| 2023 | 306 |
| 2024 | 332 |
| 2025 | 463 |
| 2026 | 480 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,266 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| immune thrombocytopeniaSignal | 143 | 174.2 | 147.9 | 23,688 |
| therapy non-responderSignal | 210 | 25.4 | 22.2 | 4,876 |
| platelet count decreasedSignal | 426 | 21.7 | 19.8 | 8,390 |
| thrombocytopeniaSignal | 254 | 12.3 | 10.9 | 2,633 |
| pancytopeniaSignal | 103 | 10.0 | 8.2 | 823 |
| treatment failureSignal | 115 | 7.5 | 6.3 | 644 |
| product use in unapproved indicationSignal | 247 | 5.4 | 4.8 | 888 |
| sepsisSignal | 106 | 5.1 | 4.3 | 351 |
| anaemiaSignal | 108 | 3.1 | 2.5 | 149 |
| off label useSignal | 494 | 3.0 | 2.8 | 707 |
| pneumoniaSignal | 139 | 2.3 | 2.0 | 105 |
| drug ineffectiveSignal | 550 | 2.3 | 2.1 | 408 |
| pyrexiaSignal | 137 | 2.1 | 1.8 | 83 |
| headache | 136 | 1.2 | 1.0 | 3 |
| death | 144 | 0.9 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.